Sotagliflozin-LX-4211-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESotagliflozinCat. No.: HY-15516CAS No.: 1018899-04-1Synonyms: LX-4211; LP-802034分式: CHClOS分量: 424.94作靶点: SGLT作通路: Membrane Transporter/Ion Channel储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DM

2、SO : 100 mg/mL (235.33 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.3533 mL 11.7664 mL 23.5327 mL5 mM 0.4707 mL 2.3533 mL 4.7065 mL10 mM 0.2353 mL 1.1766 mL 2.3533 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备

3、液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.88 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.88 mM); Clear solution1/2 Master of Small Molecules 您边的

4、抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Sotagliflozin (LX-4211)是SGLT1/2抑制剂，是抗糖尿病剂。IC50 & Target SGLT1/2体外研究 LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption;markedly and significantly improved multiple measures of glycemic control, including fasting pl

5、asma glucose,oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediatedtrends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-upsingle-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly incre

6、ased glucagon-like peptide-1and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinalglucose absorption 1. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values,decreased glucose-dependent insulinotropic polypeptide (GIP) AUC values, an

7、d decreased blood glucoseexcursions during the 6 hours after a challenge with oral glucose alone 2.户使本产品发表的科研献 Mol Metab. 2019 Jan;19:1-12. Biochem Pharmacol. 2016 Feb 1;101:27-39.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 in

8、hibitor, improved glycemic control in patients with type 2 diabetes in arandomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.2. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1(SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9.McePdfHeightCaution: Product has not been fully validated for medical applicat